| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CMC和CMO业务(元) | 28,967,849.66 | 73,811,914.26 | 38,041,419.88 | 54,556,282.31 | 18,893,754.99 |
| 抗肿瘤药及免疫调节剂(元) | 31,950,663.37 | 77,680,776.52 | 55,447,343.35 | 124,604,492.66 | 57,523,795.60 |
| 神经系统药物(元) | 31,068,278.65 | 94,632,612.60 | 56,449,410.59 | 179,959,744.20 | 95,147,720.99 |
| 消化道和代谢方面的药物(元) | 185,295,672.90 | 318,162,888.56 | 135,560,107.89 | 279,839,529.27 | 123,656,650.60 |
| 心血管系统药物(元) | 8,057,822.34 | 28,948,218.84 | 18,452,220.43 | 40,531,256.57 | 17,959,905.96 |
| 其他(元) | 22,937,523.17 | 54,805,723.34 | 17,450,637.78 | 42,504,565.95 | 17,877,633.77 |
| 营业成本(元) | |||||
| CMC和CMO业务(元) | 14,891,404.93 | 48,854,259.40 | 22,324,247.54 | 33,338,848.57 | 12,448,545.20 |
| 抗肿瘤药及免疫调节剂(元) | 6,003,012.80 | 12,286,810.76 | 7,914,142.42 | 29,457,947.33 | 12,290,484.78 |
| 神经系统药物(元) | 13,220,819.37 | 32,029,876.51 | 18,689,418.71 | 31,242,494.02 | 16,207,911.25 |
| 消化道和代谢方面的药物(元) | 46,846,236.33 | 79,754,542.94 | 36,868,036.27 | 65,332,382.86 | 28,182,506.45 |
| 心血管系统药物(元) | 3,114,801.99 | 8,277,712.03 | 3,922,260.59 | 9,270,637.01 | 4,001,397.60 |
| 其他(元) | 11,488,276.64 | 15,453,786.06 | 6,129,431.26 | 18,151,026.26 | 7,240,000.11 |
| 毛利(元) | |||||
| CMC和CMO业务(元) | 14,076,444.73 | 24,957,654.86 | 15,717,172.34 | 21,217,433.74 | 6,445,209.79 |
| 抗肿瘤药及免疫调节剂(元) | 25,947,650.57 | 65,393,965.76 | 47,533,200.93 | 95,146,545.33 | 45,233,310.82 |
| 神经系统药物(元) | 17,847,459.28 | 62,602,736.09 | 37,759,991.88 | 148,717,250.18 | 78,939,809.74 |
| 消化道和代谢方面的药物(元) | 138,449,436.57 | 238,408,345.62 | 98,692,071.62 | 214,507,146.41 | 95,474,144.15 |
| 心血管系统药物(元) | 4,943,020.35 | 20,670,506.81 | 14,529,959.84 | 31,260,619.56 | 13,958,508.36 |
| 其他(元) | 11,449,246.53 | 39,351,937.28 | 11,321,206.52 | 24,353,539.69 | 10,637,633.66 |
| 毛利率(%) | |||||
| CMC和CMO业务(%) | 48.59 | 33.81 | 41.32 | 38.89 | 34.11 |
| 抗肿瘤药及免疫调节剂(%) | 81.21 | 84.18 | 85.73 | 76.36 | 78.63 |
| 神经系统药物(%) | 57.45 | 66.15 | 66.89 | 82.64 | 82.97 |
| 消化道和代谢方面的药物(%) | 74.72 | 74.93 | 72.80 | 76.65 | 77.21 |
| 心血管系统药物(%) | 61.34 | 71.41 | 78.74 | 77.13 | 77.72 |
| 其他(%) | 49.91 | 71.80 | 64.88 | 57.30 | 59.50 |
| 收入构成(%) | |||||
| CMC和CMO业务(%) | 9.40 | 11.39 | 11.84 | 7.56 | 5.71 |
| 抗肿瘤药及免疫调节剂(%) | 10.36 | 11.99 | 17.25 | 17.26 | 17.38 |
| 神经系统药物(%) | 10.08 | 14.60 | 17.56 | 24.93 | 28.74 |
| 消化道和代谢方面的药物(%) | 60.11 | 49.10 | 42.18 | 38.76 | 37.35 |
| 心血管系统药物(%) | 2.61 | 4.47 | 5.74 | 5.61 | 5.42 |
| 其他(%) | 7.44 | 8.46 | 5.43 | 5.89 | 5.40 |
| 毛利构成(%) | |||||
| CMC和CMO业务(%) | 6.62 | 5.53 | 6.97 | 3.96 | 2.57 |
| 抗肿瘤药及免疫调节剂(%) | 12.20 | 14.49 | 21.07 | 17.78 | 18.04 |
| 神经系统药物(%) | 8.39 | 13.87 | 16.74 | 27.79 | 31.49 |
| 消化道和代谢方面的药物(%) | 65.09 | 52.82 | 43.76 | 40.08 | 38.08 |
| 心血管系统药物(%) | 2.32 | 4.58 | 6.44 | 5.84 | 5.57 |
| 其他(%) | 5.38 | 8.72 | 5.02 | 4.55 | 4.24 |